Instalab
logoInstalab

Epicoccum Purpurascens Mold IgE

See whether a commonly missed mold is fueling your allergy or asthma symptoms.

Should you take a Epicoccum Purpurascens Mold IgE test?

This test is most useful if any of these apply to you.

Living With Hard-to-Control Asthma
If your asthma flares unpredictably, a less common mold trigger can be hiding behind a clean basic allergy panel.
Symptoms Despite Negative Standard Panel
If you keep reacting to something but routine allergy testing is negative, an extended mold panel can catch what was missed.
Living or Working in Damp Spaces
If you suspect indoor mold from leaks, basements, or older buildings, this helps tie your symptoms to a specific exposure.
Already Diagnosed With Mold Allergy
If you know you react to one mold, mapping your full sensitization profile can change how you avoid triggers and choose treatment.

About Epicoccum Purpurascens Mold IgE

Mold allergy testing usually focuses on the big four: Alternaria, Aspergillus, Cladosporium, and Penicillium. Epicoccum purpurascens, also called Epicoccum nigrum, gets less attention but is a common outdoor airborne mold that can drive the same congestion, wheeze, and skin flares, and it sits on extended laboratory panels precisely because routine testing misses it.

This test measures IgE (immunoglobulin E, an antibody your immune system uses to flag specific allergens) directed at Epicoccum proteins. A measurable result means your body has decided this mold is an enemy, which can translate into symptoms when spore counts rise outdoors in late summer and fall, or in damp indoor spaces.

Why Mold-Specific Antibodies Matter

Mold spores can land in your airways, eyes, or skin and trigger a chain reaction. Once you have made IgE against a mold protein, that antibody attaches to immune cells called mast cells. The next time you inhale the spore, the mast cells dump histamine and other chemicals that cause sneezing, runny nose, itchy eyes, coughing, or asthma flares.

Epicoccum produces a major allergen called Epi p 1, a serine protease (an enzyme that cuts proteins). Lab studies confirm Epi p 1 can directly trigger histamine release from sensitized cells, which helps explain why some people develop strong reactions despite Epicoccum being less famous than other molds.

Asthma and Severe Airway Disease

Mold sensitization as a group, including molds like Epicoccum, has been tied to more severe asthma and more frequent flares. A cross-sectional study from the European Community Respiratory Health Survey of 1,132 adults found that sensitization to airborne molds (Alternaria or Cladosporium) was a significant risk factor for severe asthma. Among children with asthma, those sensitized to molds had lower lung function and more airway twitchiness than unsensitized children.

Most of this evidence pools several molds together rather than isolating Epicoccum specifically. The signal is consistent: if you have asthma or chronic airway disease and you test positive to multiple molds, your risk of poor control is meaningfully higher than people without mold sensitization.

How Epicoccum Fits in the Mold Allergy Picture

A serology dataset of about 1.6 million U.S. patients tested for IgE against 17 fungi, including Epicoccum, found that co-sensitization patterns track how closely related the molds are. Translation: a positive Epicoccum result usually points to a group of related fungi rather than to Epicoccum alone, because the antibodies your immune system makes can cross-react across similar mold proteins.

An older study using an extended mold panel in 121 asthmatic children found that adding Epicoccum and other less common molds revealed mold-specific IgE in about 8% of mold-RAST-positive children that the standard panel alone would have missed. That is a small but real catch, and it explains why allergists order broad mold panels when symptoms point to mold but routine testing comes back clean.

Reference Ranges

Allergen-specific IgE results vary by lab, by assay, and by individual factors like age and total IgE. The thresholds below come from the widely used ImmunoCAP system (a common laboratory method for measuring specific IgE) and similar assays. They are orientation, not a target. Always compare your results within the same lab over time.

ClassRange (kU/L)What It Suggests
0Less than 0.35No detectable sensitization
10.35 to 0.69Low-level sensitization, may or may not match symptoms
20.70 to 3.49Moderate sensitization
33.50 to 17.49High sensitization, often clinically meaningful
417.5 to 49.9Very high sensitization
550 to 99.9Very high sensitization
6100 or higherExtremely high sensitization, strong allergic phenotype likely

A positive number does not automatically mean you are clinically allergic. It means your immune system has produced antibodies against this mold. The result needs to be interpreted alongside your symptoms, your exposure history, and ideally a skin test if there is doubt.

When Results Can Be Misleading

  • Total IgE level: people with very high overall IgE (such as those with eczema or parasitic infection) can show low-level positive results to many allergens, including molds, without true clinical allergy.
  • Lab assay differences: results from different commercial systems do not always agree, especially for less common molds. A change in lab can shift your number even if your biology has not changed.
  • Recent allergen exposure: heavy exposure to one mold can raise IgE to related molds through cross-reactivity, even if the second mold is not your real driver.
  • Age and sex: total IgE peaks in children, drops with age, and is generally lower in females. This shifts the baseline against which a specific IgE is interpreted.

Tracking Your Trend

A single result is a snapshot of an immune system that changes with seasons, exposures, illness, and treatment. If you are starting allergen immunotherapy, moving to a new home, remediating mold, or beginning a biologic medication, retesting in 6 to 12 months tells you whether your sensitization is shifting. For stable readers without intervention, an annual retest is reasonable to track trajectory.

Stick with the same lab and same assay for trend reliability. A jump from class 2 to class 4 in the same lab is meaningful. The same numerical jump across two different methods may be noise.

What to Do With an Abnormal Result

A positive Epicoccum result by itself is not a diagnosis. The next step is to connect the number to your real-world symptoms and exposures. Pair this test with total IgE and at least the standard mold panel (Alternaria, Aspergillus, Cladosporium, Penicillium) to see whether you are mono-sensitized or part of a broader mold-reactive pattern. If you have asthma or chronic sinus disease and multiple molds light up, that pattern is worth showing to an allergist who can decide whether skin testing, mold remediation at home, or allergen immunotherapy belongs in your plan.

If you live or work in a damp building, indoor air assessment and visible mold remediation are practical first steps regardless of your specific IgE level. The goal is to lower your exposure load so that your immune system has less to react to.

What Moves This Biomarker

Evidence-backed interventions that affect your Epicoccum Purpurascens Mold IgE level

Decrease
Omalizumab (an injectable anti-IgE biologic medication)
Omalizumab binds free IgE in the blood and lowers total circulating IgE in patients with allergic asthma and other allergic diseases. The drug is approved for moderate to severe allergic asthma and chronic urticaria, and its effect on free IgE is consistent and well documented. The direct effect on Epicoccum-specific IgE has not been isolated in published trials, but free IgE reduction applies across allergen specificities.
MedicationStrong Evidence
Up & Down
Allergen-specific immunotherapy (allergy shots or sublingual drops) for mold allergens
Allergen immunotherapy is designed to retrain your immune system away from the allergic response. In randomized trials of related molds (Cladosporium and Alternaria, not Epicoccum specifically), it reduced symptoms and medication use, and shifted IgE compartments over time. Specific IgE often rises in the first months of treatment before falling later. Direct effect on Epicoccum-specific IgE has not been measured in published trials.
MedicationModerate Evidence
Decrease
Reducing indoor mold exposure through humidity control and remediation
Long-term observational data link visible indoor mold and dampness to higher rates of asthma and rhinitis, especially in children. Lowering exposure is a foundational step in mold allergy management. Direct measurement of changes in Epicoccum-specific IgE after remediation has not been published, so the case for remediation rests on symptom reduction rather than a guaranteed drop in this number.
LifestyleModest Evidence

Frequently Asked Questions

References

16 studies
  1. Letovsky S, Robinson M, Kwong K, Liu AH, Sullivan a, Valcour aAnnals of Allergy, Asthma & Immunology2023
  2. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch FBMJ2002
  3. Byeon JH, Ri S, Amarsaikhan O, Kim E, Ahn SY, Choi IS, Kim HJ, Seo S, Yoon W, Yoo YAllergy, Asthma & Immunology Research2017